InspireMD (NSPR)
(Delayed Data from NSDQ)
$2.91 USD
-0.05 (-1.69%)
Updated Aug 16, 2024 04:00 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NSPR 2.91 -0.05(-1.69%)
Will NSPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NSPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NSPR
InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates
Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates
NSPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Other News for NSPR
InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript
NSPR Stock Earnings: InspireMD Misses EPS, Misses Revenue for Q2 2024
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
InspireMD GAAP EPS of -$0.22, revenue of $1.74M
InspireMD reports Q2 EPS (22c) vs (24c) last year